Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.

Hope S Rugo, Aditya Bardia, Sara Tolaney

Registry-linked trialAbstract readLetterComment

In one paragraph

Article in Lancet (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03901339 (Phase 3 Study of Sacituzumab Govitecan), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03901339 phase3completednot on this map

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens

TypeinterventionalSponsorGilead SciencesRan2019 to 2023Enrolled543ConditionsMetastatic Breast CancerArmsSacituzumab Govitecan-hziy, Eribulin, Capecitabine, Gemcitabine, Vinorelbine

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Hope S RugoDepartment of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94158, USA. Electronic address: hope.rugo@ucsf.edu.

Aditya BardiaDavid Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA.

Sara TolaneyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedBreast NeoplasmsAntineoplastic Agents, ImmunologicalCamptothecinFemaleHumansImmunoconjugatesNeoplasm MetastasisAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCamptothecinImmunoconjugatessacituzumab govitecan

Identifiers

PMID39067902

DOI10.1016/S0140-6736(24)01049-3

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT03901339ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.